Sec Form 3 Filing - Morrone Louis H. @ ABBOTT LABORATORIES - 2021-07-01

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Morrone Louis H. 2. Issuer Name and Ticker or Trading Symbol ABBOTT LABORATORIES [ ABT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) SENIOR VICE PRESIDENT (Last) (First) (Middle) 100 ABBOTT PARK ROAD 3. Date of Earliest Transaction (MM/DD/YY) 07/01/2021 (Street) ABBOTT PARK, IL60064 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common shares without par value 34,465 D Common shares without par value 2,268 ( 1 ) I Profit Sharing Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Option (right to buy) ( 2 ) $ 48.34 07/10/2018 07/09/2027 Common Shares 29,965 D Option (right to buy) ( 3 ) $ 59.94 02/16/2019 02/15/2028 Common Shares 51,559 D Option (right to buy) ( 4 ) $ 75.9 02/22/2020 02/21/2029 Common Shares 38,190 D Option (right to buy) ( 5 ) $ 87.72 02/21/2021 02/20/2030 Common Shares 35,469 D Option (right to buy) ( 6 ) $ 124.04 02/19/2022 02/18/2031 Common Shares 22,272 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Morrone Louis H. 100 ABBOTT PARK ROAD ABBOTT PARK, IL60064 SENIOR VICE PRESIDENT Signatures /s/ Louis H. Morrone by Jessica H. Paik, Attorney-in-Fact 07/06/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Balance in the Abbott Laboratories Stock Retirement Trust as of July 1, 2021. ( 2 )Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 9,989 on July 10, 2018, 9,988 on July 10, 2019, and 9,988 on July 10, 2020. ( 3 )Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 17,187 on February 16, 2019 and 17,186 on February 16, 2020, and an increment of 17,186 becomes exercisable on February 16, 2021. ( 4 )Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 12,730 on February 22, 2020 and 12,730 on February 22, 2021, and an increment of 12,730 becomes exercisable on February 22, 2022. ( 5 )Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in an annual increment of 11,823 on February 21, 2021 and annual increments of 11,823 become exercisable on each of February 21, 2022 and February 21, 2023. ( 6 )Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,424 on February 19, 2022, 7,424 on February 19, 2023 and 7,424 on February 19, 2024.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.